COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
01/02/2024
Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
01/02/2024
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Quipt Home Medical Corp. to Announce Fiscal First Quarter 2024 Financial Results on February 14, 2024
01/02/2024
CINCINNATI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce [...]
Dyne Therapeutics to Present at February Investor Conferences
01/02/2024
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
01/02/2024
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy metabolism by inhibiting [...]
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
01/02/2024
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process [...]
ITM Obtains Manufacturing License in the U.S.
01/02/2024
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and Princeton, NJ, February 1, 2024 – ITM [...]
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
01/02/2024
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim 6 th [...]
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and [...]
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
01/02/2024
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta [...]
Applied UV, Inc. to Develop Smart Building Technologies for Larimar City, a New Luxury Development With Six Hotels and 20,000 High-end Residences - Potential Revenues Could Total $250 Million to $300 Million
01/02/2024
Max Munn, CEO of AUVI, states: “We estimate that potential revenues from this project could total $250 Million to $300 Million over the next 3 to 6 years.” AUVI subsidiaries (MunnWorks, SteriLumen & LED), in talks [...]
Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
01/02/2024
Company Previews New SpeedPlate™ Configurations, Announces Full Commercial Release of its Micro-Lapiplasty™ System and Limited Clinical Release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific [...]
Panbela Announces Closing of Approximately $9.0 Million Public Offering
01/02/2024
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
01/02/2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual [...]
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred [...]
Opthea Strengthens Team with Key Clinical and Regulatory Hires
01/02/2024
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1st Experienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, [...]
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
01/02/2024
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug [...]
Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations
01/02/2024
HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, [...]
HUTCHMED to Announce 2023 Final Results
01/02/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December [...]

Pages